Skip to main content
. Author manuscript; available in PMC: 2012 Dec 20.
Published in final edited form as: Gene Ther. 2011 Jun 30;19(1):78–85. doi: 10.1038/gt.2011.64

Figure 5. AAV capsid or hFIX specific T cells at 6 months after intramuscular delivery of rAAV2/5 CAGG hFIX.

Figure 5

A. Capsid (AAV5) or hFIX specific IFN-γ ELISpot; results are expressed in spot forming units (SFU)/106 splenocytes as average (± SD) of 3 replicates. Media = negative control; and PMA, positive control. B A representative ELISpot assay showing difference in the number of IFN-γ expressing AAV5 capsid specific T cells in splenocytes obtained from AAV untreated (-ve control) or AAV5 transduced animals with (AAV5+CyA+Ab) or without immunosuppression (AAV5 alone).